Corcept Therapeutics Incorporated (CORT)
USD 67.43
(-1.73%)
USD 67.43
(-1.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 107.28 Million USD | -4.75% |
| 2022 | 112.63 Million USD | -9.51% |
| 2021 | 124.47 Million USD | -2.91% |
| 2020 | 128.2 Million USD | 14.87% |
| 2019 | 111.6 Million USD | 24.71% |
| 2018 | 89.49 Million USD | 69.32% |
| 2017 | 52.85 Million USD | 419.26% |
| 2016 | 10.17 Million USD | 395.64% |
| 2015 | -3.44 Million USD | 87.53% |
| 2014 | -27.61 Million USD | 33.44% |
| 2013 | -41.49 Million USD | -14.4% |
| 2012 | -36.27 Million USD | -12.19% |
| 2011 | -32.33 Million USD | -17.84% |
| 2010 | -27.43 Million USD | -35.49% |
| 2009 | -20.25 Million USD | -2.85% |
| 2008 | -19.68 Million USD | -60.79% |
| 2007 | -12.24 Million USD | 52.13% |
| 2006 | -25.58 Million USD | -20.91% |
| 2005 | -21.15 Million USD | -31.87% |
| 2004 | -16.04 Million USD | -60.54% |
| 2003 | -9.99 Million USD | 46.82% |
| 2002 | -18.79 Million USD | -134.76% |
| 2001 | -8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 29.5 Million USD | -6.85% |
| 2024 Q2 | 35.59 Million USD | 20.65% |
| 2024 Q3 | 46.59 Million USD | 30.92% |
| 2023 Q2 | 29.58 Million USD | 99.17% |
| 2023 Q4 | 31.66 Million USD | 1.58% |
| 2023 FY | 107.28 Million USD | -4.75% |
| 2023 Q1 | 14.85 Million USD | -33.98% |
| 2023 Q3 | 31.17 Million USD | 5.39% |
| 2022 Q4 | 22.49 Million USD | -29.55% |
| 2022 Q3 | 31.93 Million USD | 1.6% |
| 2022 Q2 | 31.43 Million USD | 17.42% |
| 2022 FY | 112.63 Million USD | -9.51% |
| 2022 Q1 | 26.76 Million USD | -26.99% |
| 2021 FY | 124.47 Million USD | -2.91% |
| 2021 Q2 | 31.94 Million USD | 62.66% |
| 2021 Q4 | 36.66 Million USD | 1.19% |
| 2021 Q1 | 19.63 Million USD | -35.63% |
| 2021 Q3 | 36.23 Million USD | 13.43% |
| 2020 Q2 | 35.26 Million USD | -6.49% |
| 2020 FY | 128.2 Million USD | 14.87% |
| 2020 Q1 | 37.71 Million USD | 7.7% |
| 2020 Q3 | 24.71 Million USD | -29.9% |
| 2020 Q4 | 30.51 Million USD | 23.43% |
| 2019 Q4 | 35.01 Million USD | 6.1% |
| 2019 Q3 | 33 Million USD | 33.98% |
| 2019 FY | 111.6 Million USD | 24.71% |
| 2019 Q2 | 24.63 Million USD | 29.95% |
| 2019 Q1 | 18.95 Million USD | -23.87% |
| 2018 Q3 | 22.96 Million USD | 11.32% |
| 2018 Q4 | 24.89 Million USD | 8.4% |
| 2018 FY | 89.49 Million USD | 69.32% |
| 2018 Q1 | 20.99 Million USD | -3.24% |
| 2018 Q2 | 20.63 Million USD | -1.72% |
| 2017 Q3 | 13.62 Million USD | 6.47% |
| 2017 Q4 | 21.69 Million USD | 59.27% |
| 2017 FY | 52.85 Million USD | 419.26% |
| 2017 Q1 | 4.74 Million USD | -5.33% |
| 2017 Q2 | 12.79 Million USD | 169.94% |
| 2016 Q2 | 1.5 Million USD | 154.73% |
| 2016 Q1 | 592 Thousand USD | -64.14% |
| 2016 FY | 10.17 Million USD | 395.64% |
| 2016 Q4 | 5 Million USD | 62.99% |
| 2016 Q3 | 3.07 Million USD | 103.71% |
| 2015 Q3 | 102 Thousand USD | 108.75% |
| 2015 FY | -3.44 Million USD | 87.53% |
| 2015 Q4 | 1.65 Million USD | 1518.63% |
| 2015 Q2 | -1.16 Million USD | 71.07% |
| 2015 Q1 | -4.03 Million USD | -30.97% |
| 2014 Q4 | -3.07 Million USD | 39.7% |
| 2014 FY | -27.61 Million USD | 33.44% |
| 2014 Q1 | -12.85 Million USD | -28.21% |
| 2014 Q2 | -6.58 Million USD | 48.82% |
| 2014 Q3 | -5.1 Million USD | 22.46% |
| 2013 Q3 | -9.74 Million USD | 9.67% |
| 2013 Q1 | -10.94 Million USD | -9.65% |
| 2013 FY | -41.49 Million USD | -14.4% |
| 2013 Q4 | -10.03 Million USD | -2.98% |
| 2013 Q2 | -10.78 Million USD | 1.46% |
| 2012 Q1 | -11.02 Million USD | -11.09% |
| 2012 Q4 | -9.98 Million USD | -30.1% |
| 2012 Q3 | -7.67 Million USD | -1.04% |
| 2012 FY | -36.27 Million USD | -12.19% |
| 2012 Q2 | -7.59 Million USD | 31.16% |
| 2011 Q2 | -8.86 Million USD | -24.95% |
| 2011 Q3 | -6.43 Million USD | 27.42% |
| 2011 FY | -32.33 Million USD | -17.84% |
| 2011 Q4 | -9.92 Million USD | -54.23% |
| 2011 Q1 | -7.09 Million USD | 9.28% |
| 2010 Q2 | -6.44 Million USD | -6.28% |
| 2010 Q4 | -7.82 Million USD | -10.12% |
| 2010 FY | -27.43 Million USD | -35.49% |
| 2010 Q3 | -7.1 Million USD | -10.24% |
| 2010 Q1 | -6.06 Million USD | -17.45% |
| 2009 Q3 | -4.67 Million USD | 4.34% |
| 2009 Q1 | -5.53 Million USD | 8.03% |
| 2009 FY | -20.25 Million USD | -2.85% |
| 2009 Q4 | -5.16 Million USD | -10.56% |
| 2009 Q2 | -4.88 Million USD | 11.78% |
| 2008 FY | -19.68 Million USD | -60.79% |
| 2008 Q4 | -6.01 Million USD | -22.75% |
| 2008 Q3 | -4.9 Million USD | -4.59% |
| 2008 Q1 | -4.08 Million USD | 7.6% |
| 2008 Q2 | -4.68 Million USD | -14.79% |
| 2007 Q1 | -2.62 Million USD | 34.15% |
| 2007 Q2 | -1.57 Million USD | 39.92% |
| 2007 Q3 | -3.61 Million USD | -129.13% |
| 2007 FY | -12.24 Million USD | 52.13% |
| 2007 Q4 | -4.41 Million USD | -22.14% |
| 2006 Q1 | -6.97 Million USD | -26.78% |
| 2006 Q4 | -3.99 Million USD | 39.06% |
| 2006 Q3 | -6.54 Million USD | 18.79% |
| 2006 Q2 | -8.06 Million USD | -15.55% |
| 2006 FY | -25.58 Million USD | -20.91% |
| 2005 Q1 | -5.78 Million USD | -4.79% |
| 2005 Q3 | -5.48 Million USD | -24.97% |
| 2005 Q4 | -5.5 Million USD | -0.44% |
| 2005 FY | -21.15 Million USD | -31.87% |
| 2005 Q2 | -4.38 Million USD | 24.21% |
| 2004 Q4 | -5.52 Million USD | -29.7% |
| 2004 Q1 | -2.57 Million USD | -25.76% |
| 2004 Q3 | -4.25 Million USD | -15.25% |
| 2004 FY | -16.04 Million USD | -60.54% |
| 2004 Q2 | -3.69 Million USD | -43.75% |
| 2003 Q3 | -2.16 Million USD | 26.03% |
| 2003 Q2 | -2.92 Million USD | -1.99% |
| 2003 FY | -9.99 Million USD | 46.82% |
| 2003 Q1 | -2.86 Million USD | 0.0% |
| 2003 Q4 | -2.04 Million USD | 5.47% |
| 2002 FY | -18.79 Million USD | -134.76% |
| 2001 FY | -8 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Agenus Inc. | -159.54 Million USD | 167.241% |
| Immix Biopharma, Inc. | -16.14 Million USD | 764.651% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 163.129% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 192.437% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 128.195% |
| MiMedx Group, Inc. | 37.11 Million USD | -189.045% |
| Novavax, Inc. | -566.51 Million USD | 118.937% |
| Seer, Inc. | -103.46 Million USD | 203.691% |
| Acelyrin, Inc. | -422.06 Million USD | 125.418% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 343.767% |
| IO Biotech, Inc. | -91.44 Million USD | 217.321% |
| Ardelyx, Inc. | -63.27 Million USD | 269.546% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 177.164% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 337.996% |
| Fortress Biotech, Inc. | -142.34 Million USD | 175.369% |
| Fortress Biotech, Inc. | -142.34 Million USD | 175.369% |
| Geron Corporation | -193.94 Million USD | 155.316% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 152.332% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 209.814% |
| Incyte Corporation | 620.52 Million USD | 82.711% |
| Innoviva, Inc. | 176.7 Million USD | 39.289% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 1361.993% |
| ChromaDex Corporation | -5.59 Million USD | 2016.092% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -798.359% |
| MEI Pharma, Inc. | 14.54 Million USD | -637.739% |
| NextCure, Inc. | -67.63 Million USD | 258.614% |
| Onconetix, Inc. | -36.03 Million USD | 397.719% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 357.185% |
| GlycoMimetics, Inc. | -39.27 Million USD | 373.154% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 179.806% |
| Vaxcyte, Inc. | -468.04 Million USD | 122.921% |
| Precigen, Inc. | -88.92 Million USD | 220.646% |
| Pharming Group N.V. | -4.87 Million USD | 2298.607% |
| ContextLogic Inc. | -328 Million USD | 132.708% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 1655.262% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 230.52% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 623.557% |
| AlloVir, Inc. | -181.33 Million USD | 159.164% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 541.37% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 181.593% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 832069.749% |
| Summit Therapeutics Inc. | -89.73 Million USD | 219.553% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 146.654% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 389.451% |
| Senti Biosciences, Inc. | -92.72 Million USD | 215.697% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 162.452% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 413.077% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 3492.853% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 3998.576% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 301.937% |
| Chimerix, Inc. | -93.06 Million USD | 215.276% |
| PDS Biotechnology Corporation | -43.04 Million USD | 349.231% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 711.677% |
| CRISPR Therapeutics AG | -222.53 Million USD | 148.208% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 257.777% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 164.121% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 460.539% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 210.932% |
| Precision BioSciences, Inc. | -43.73 Million USD | 345.294% |
| Dyadic International, Inc. | -8.22 Million USD | 1403.589% |
| Elevation Oncology, Inc. | -45.44 Million USD | 336.07% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 9100.168% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 331.931% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 138.02% |
| Aptorum Group Limited | -10.52 Million USD | 1119.468% |
| Bicycle Therapeutics plc | -189.94 Million USD | 156.48% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 2821.479% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 531.823% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 634.012% |
| GT Biopharma, Inc. | -13.57 Million USD | 890.233% |
| Alkermes plc | 414.12 Million USD | 74.094% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 263.144% |
| Jaguar Health, Inc. | -34.29 Million USD | 412.858% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 424.89% |
| AbCellera Biologics Inc. | -237.2 Million USD | 145.227% |
| PureTech Health plc | -146.19 Million USD | 173.381% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 652.473% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 139.153% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 383.298% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 227.848% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 541.37% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 249.142% |
| AnaptysBio, Inc. | -164.41 Million USD | 165.252% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 416.99% |
| ESSA Pharma Inc. | -32.13 Million USD | 433.857% |
| Molecular Templates, Inc. | -10.46 Million USD | 1125.053% |
| Scopus BioPharma Inc. | -11.71 Million USD | 1015.776% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 121.273% |
| Vaxxinity, Inc. | -58.28 Million USD | 284.065% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 311.631% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 466.088% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 247.004% |
| Structure Therapeutics Inc. | -102.77 Million USD | 204.385% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 289.013% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 193.473% |
| ImmuCell Corporation | -5.74 Million USD | 1966.398% |
| Lantern Pharma Inc. | -17.87 Million USD | 700.093% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 466.676% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 1115.639% |
| Opthea Limited | -191.84 Million USD | 155.922% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 145.536% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 183.172% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 156.313% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 148.938% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -23.58% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 308.29% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 1179.552% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 141.316% |
| Aptose Biosciences Inc. | -52.35 Million USD | 304.909% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 843.941% |
| Soligenix, Inc. | -7.69 Million USD | 1493.646% |
| Century Therapeutics, Inc. | -146.54 Million USD | 173.207% |
| Kura Oncology, Inc. | -165.8 Million USD | 164.704% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 214.792% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 1389.602% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 4423.03% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 1754.565% |
| Autolus Therapeutics plc | -195.02 Million USD | 155.009% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 226.725% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 245.641% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 607.604% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 147.254% |
| GRI Bio, Inc. | -11.38 Million USD | 1042.145% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 2475.748% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 181.774% |
| IGM Biosciences, Inc. | -263.46 Million USD | 140.72% |
| INmune Bio, Inc. | -29.74 Million USD | 460.721% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 196.987% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 381.763% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 771.379% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 780.256% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 275.59% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 199.777% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 138.869% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 152.797% |
| Verastem, Inc. | -92.08 Million USD | 216.504% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 327.606% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 158.26% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 190.625% |
| Histogen Inc. | -10.64 Million USD | 1108.005% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 793.396% |
| Surrozen, Inc. | -45.78 Million USD | 334.343% |
| Organovo Holdings, Inc. | -15.08 Million USD | 811.136% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 2207.604% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 280.971% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 309.151% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 524.375% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 1505.531% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 162.634% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 321.438% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 237.18% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 804.839% |
| Apollomics, Inc. | -54.83 Million USD | 295.649% |
| Amarin Corporation plc | -67.58 Million USD | 258.729% |
| Mesoblast Limited | -58.79 Million USD | 282.471% |
| Turnstone Biologics Corp. | -59.03 Million USD | 281.735% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 164.811% |
| Synaptogenix, Inc. | -8.31 Million USD | 1390.4% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 835.514% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 217.004% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 2339.022% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 1314.802% |
| Exelixis, Inc. | 170.88 Million USD | 37.22% |
| Better Therapeutics, Inc. | -38.26 Million USD | 380.388% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 169.186% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 120.746% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1008.626% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 1434.037% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 457.69% |
| Gritstone bio, Inc. | -154.63 Million USD | 169.378% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 255.795% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 726.536% |
| Avid Bioservices, Inc. | -18.67 Million USD | 674.376% |
| Insmed Incorporated | -709.62 Million USD | 115.118% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 783.77% |
| MediWound Ltd. | -15.29 Million USD | 801.648% |
| OmniAb, Inc. | -69.41 Million USD | 254.543% |
| Alector, Inc. | -151.74 Million USD | 170.701% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 199.351% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 305.726% |
| Zai Lab Limited | -366.57 Million USD | 129.266% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 133.867% |
| Aura Biosciences, Inc. | -84.99 Million USD | 226.227% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 143.7% |
| Immunic, Inc. | -99.22 Million USD | 208.122% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 174.94% |
| Veracyte, Inc. | -85.79 Million USD | 225.045% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 138.068% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 854.975% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 1657.532% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 670.873% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 81.458% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 521.491% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -176.486% |
| TG Therapeutics, Inc. | 20.63 Million USD | -419.953% |
| Galecto, Inc. | -39.9 Million USD | 368.844% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 354.984% |
| Fortrea Holdings Inc. | 63.1 Million USD | -70.019% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 176.387% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 471.501% |
| XBiotech Inc. | -37.51 Million USD | 386.009% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 255.795% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 259.836% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 199.422% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 517.895% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 301.31% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 118.848% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 236.679% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 203.445% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 582.098% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 224.146% |
| NexImmune, Inc. | -29.19 Million USD | 467.499% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 2008.888% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 835.747% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 97.349% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 521.391% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 184.433% |
| Ainos, Inc. | -13.2 Million USD | 912.349% |
| Pluri Inc. | -22.15 Million USD | 584.168% |
| Prothena Corporation plc | -191.03 Million USD | 156.158% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 177.719% |
| Celularity Inc. | -192.28 Million USD | 155.793% |
| Rallybio Corporation | -78.93 Million USD | 235.917% |
| Cue Biopharma, Inc. | -52.14 Million USD | 305.722% |
| MeiraGTx Holdings plc | -137.06 Million USD | 178.273% |
| Omeros Corporation | -164.53 Million USD | 165.205% |
| Humacyte, Inc. | -100.04 Million USD | 207.232% |
| Immunocore Holdings plc | -59.64 Million USD | 279.855% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 678.059% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 538.19% |
| Blueprint Medicines Corporation | -486.27 Million USD | 122.062% |
| CalciMedica, Inc. | -21.87 Million USD | 590.432% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 243.694% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 162.63% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 132.818% |
| Pulmatrix, Inc. | -14.74 Million USD | 827.829% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 400.131% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 220.723% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 120.82% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 258.816% |
| Cytokinetics, Incorporated | -496.2 Million USD | 121.62% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 411.694% |
| Nutriband Inc. | -4.87 Million USD | 2302.045% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 345.986% |
| Vor Biopharma Inc. | -126.03 Million USD | 185.12% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 97.471% |
| Evogene Ltd. | -26.39 Million USD | 506.51% |
| ProKidney Corp. | -151.52 Million USD | 170.803% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 266.238% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 1494.678% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 117.663% |
| CorMedix Inc. | -48.95 Million USD | 319.132% |
| BioLineRx Ltd. | -49.69 Million USD | 315.885% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 193.964% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 381.787% |
| Atai Life Sciences N.V. | -125.47 Million USD | 185.503% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 231.41% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 231.781% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 143.087% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 448.998% |
| MediciNova, Inc. | -9.9 Million USD | 1183.628% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 184.893% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 1581.292% |
| GeoVax Labs, Inc. | -26.74 Million USD | 501.16% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 146.277% |
| Biomea Fusion, Inc. | -126.13 Million USD | 185.053% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 130.704% |
| Mereo BioPharma Group plc | -28.41 Million USD | 477.541% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 156.142% |
| Absci Corporation | -115.51 Million USD | 192.873% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 488.886% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 195.052% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 144.302% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 525.79% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 151.579% |
| Allakos Inc. | -196.05 Million USD | 154.72% |
| Imunon, Inc. | -21.03 Million USD | 610.127% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 196.944% |
| BioAtla, Inc. | -129.68 Million USD | 182.724% |
| NLS Pharmaceutics AG | -11.8 Million USD | 1008.626% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 777.157% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 132.734% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 356.914% |
| XOMA Corporation | -41.84 Million USD | 356.361% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 201.943% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 188.302% |
| aTyr Pharma, Inc. | -54.91 Million USD | 295.346% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 222.71% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 162.059% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 142.162% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 599.776% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 1406.285% |
| Akari Therapeutics, Plc | -16.8 Million USD | 738.355% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 1213281.455% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 68.22% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 1741.898% |
| UroGen Pharma Ltd. | -65.53 Million USD | 263.699% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 220.166% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 1577.101% |
| Orgenesis Inc. | -53.63 Million USD | 300.019% |
| Entera Bio Ltd. | -8.89 Million USD | 1306.636% |
| GH Research PLC | -41.22 Million USD | 360.254% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 517.31% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 229.173% |
| Xencor, Inc. | -138.63 Million USD | 177.382% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 2181.293% |
| Replimune Group, Inc. | -234.77 Million USD | 145.696% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 599.192% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 868.936% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 1741.898% |
| Portage Biotech Inc. | -18.25 Million USD | 687.75% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 1581.292% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 202.211% |
| OncoCyte Corporation | -25.13 Million USD | 526.806% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1048.99% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 1036.383% |
| Purple Biotech Ltd. | 22.27 Million USD | -381.712% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 1528.142% |
| scPharmaceuticals Inc. | -55.39 Million USD | 293.664% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 667.699% |
| HilleVax, Inc. | -133.34 Million USD | 180.454% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 990.381% |
| Tharimmune, Inc. | -9.45 Million USD | 1234.633% |
| Genprex, Inc. | -31.07 Million USD | 445.229% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 157.006% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 441.913% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 14123.791% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 2069.591% |
| OKYO Pharma Limited | -15.74 Thousand USD | 681267.233% |
| Savara Inc. | -60 Million USD | 278.782% |
| Curis, Inc. | -48.33 Million USD | 321.969% |
| Daré Bioscience, Inc. | -30.83 Million USD | 447.868% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 2156.282% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 1574.261% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 493.695% |
| BeiGene, Ltd. | -1.2 Billion USD | 108.883% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 638.043% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 122.021% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 214.554% |
| Erasca, Inc. | -141.52 Million USD | 175.804% |
| bluebird bio, Inc. | -244.26 Million USD | 143.921% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 2469.839% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 44.825% |
| DBV Technologies S.A. | -76.43 Million USD | 240.363% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 2469.839% |
| Moderna, Inc. | -4.23 Billion USD | 102.531% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 351.782% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 1786.824% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 259.558% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 128.476% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 174.86% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 306.339% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 169.419% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 151.546% |
| MacroGenics, Inc. | -168.24 Million USD | 163.766% |
| RenovoRx, Inc. | -11.39 Million USD | 1041.4% |
| Adicet Bio, Inc. | -152.03 Million USD | 170.563% |
| Prime Medicine, Inc. | -191.29 Million USD | 156.083% |
| Aditxt, Inc. | -26.06 Million USD | 511.635% |
| Adagene Inc. | -23.71 Million USD | 552.288% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1567.586% |
| Quantum-Si incorporated | -111.17 Million USD | 196.502% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 438.985% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 835.929% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 12.074% |
| SciSparc Ltd. | -5.77 Million USD | 1958.341% |
| Vericel Corporation | -6.46 Million USD | 1759.684% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 1339.3% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 564.031% |
| Generation Bio Co. | -138.56 Million USD | 177.425% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 229.209% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 224.083% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 144.497% |
| Invivyd, Inc. | -207.78 Million USD | 151.632% |
| Relay Therapeutics, Inc. | -373 Million USD | 128.762% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 1243.914% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -399.427% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 1142.889% |
| 2seventy bio, Inc. | -216.7 Million USD | 149.506% |
| ADMA Biologics, Inc. | 21.63 Million USD | -395.941% |
| Clene Inc. | -40.54 Million USD | 364.632% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 545.563% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 295.784% |
| GeoVax Labs, Inc. | -26.74 Million USD | 501.16% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 130.647% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 392.067% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -567.301% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 203.452% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 415.517% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 163.004% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 115.678% |
| Evaxion Biotech A/S | -22.19 Million USD | 583.318% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 230.225% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 148.082% |
| Trevena, Inc. | -35.28 Million USD | 404.018% |
| Surrozen, Inc. | -45.78 Million USD | 334.343% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 234.195% |
| Cingulate Inc. | -22.75 Million USD | 571.379% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -1331.954% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 340.182% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 1402.924% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 204.606% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 246.203% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 272.829% |
| Clearmind Medicine Inc. | -8.74 Million USD | 1327.293% |
| Kronos Bio, Inc. | -121.83 Million USD | 188.059% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 240.797% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 3757.775% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 206.402% |
| Statera Biopharma, Inc. | -98.34 Million USD | 209.089% |
| ImmunityBio, Inc. | -362.25 Million USD | 129.615% |
| Korro Bio, Inc. | -84.53 Million USD | 226.91% |
| Kineta, Inc. | -15.72 Million USD | 782.325% |
| BioVie Inc. | -32.17 Million USD | 433.385% |
| Codexis, Inc. | -68.06 Million USD | 257.608% |
| Celularity Inc. | -192.28 Million USD | 155.793% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 148.193% |
| Celcuity Inc. | -66.23 Million USD | 261.983% |
| Virax Biolabs Group Limited | -6.49 Million USD | 1751.388% |
| Cibus, Inc. | -318.88 Million USD | 133.643% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 349.493% |
| IN8bio, Inc. | -30.33 Million USD | 453.634% |
| Kodiak Sciences Inc. | -277.32 Million USD | 138.685% |
| Annexon, Inc. | -143.72 Million USD | 174.645% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 186.664% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 265.953% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 557.61% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 130.329% |
| Eyenovia, Inc. | -25.4 Million USD | 522.263% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -228.683% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 2028.839% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 235.572% |
| Arcellx, Inc. | -89.88 Million USD | 219.361% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 336.242% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 178.19% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 444.858% |
| Moolec Science SA | -6.65 Million USD | 1712.341% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 275.475% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 348.034% |
| Royalty Pharma plc | 1.49 Billion USD | 92.81% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 165.351% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1250.124% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 589.992% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 162.754% |
| Humacyte, Inc. | -100.04 Million USD | 207.232% |
| 89bio, Inc. | -151.2 Million USD | 170.952% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 233.882% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 837.84% |
| Genelux Corporation | -24.16 Million USD | 543.956% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 416.252% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 162.464% |
| Notable Labs, Ltd. | -14.65 Million USD | 831.951% |
| Liquidia Corporation | -73.38 Million USD | 246.193% |
| Mustang Bio, Inc. | -50.72 Million USD | 311.493% |
| Immunovant, Inc. | -282.7 Million USD | 137.948% |
| Quantum-Si incorporated | -111.17 Million USD | 196.502% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 237.36% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 604.453% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 205.166% |
| Acasti Pharma Inc. | -11.31 Million USD | 1048.391% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 568.049% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 771.379% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 150.119% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 3023.955% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 775.324% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 467.946% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 359.235% |
| PepGen Inc. | -84.76 Million USD | 226.563% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 462.06% |
| United Therapeutics Corporation | 1.18 Billion USD | 90.946% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 568.542% |
| Solid Biosciences Inc. | -104.31 Million USD | 202.844% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 426.998% |
| Immuneering Corporation | -58.41 Million USD | 283.662% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 2207.604% |
| Silo Pharma, Inc. | -3.85 Million USD | 2882.504% |
| Belite Bio, Inc | -31.66 Million USD | 438.771% |
| XOMA Corporation | -41.84 Million USD | 356.361% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 258.889% |
| Bionomics Limited | -17.89 Billion USD | 100.6% |
| Apogee Therapeutics, Inc. | -93 Million USD | 215.353% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -200.678% |
| uniQure N.V. | -282.87 Million USD | 137.926% |
| Cassava Sciences, Inc. | -105.95 Million USD | 201.251% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1567.586% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 182.841% |
| Forte Biosciences, Inc. | -32.48 Million USD | 430.241% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 1391.192% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 464.967% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 2028.839% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 854.975% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 1306.907% |
| Altimmune, Inc. | -95.92 Million USD | 211.835% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 245.974% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -200.678% |
| Compugen Ltd. | -12.99 Million USD | 925.754% |
| Peak Bio, Inc. | -1356.23 USD | 7910410.198% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 316.277% |
| Benitec Biopharma Inc. | -22.49 Million USD | 577.021% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 144.276% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 460.66% |
| Zura Bio Limited | -62.63 Million USD | 271.273% |
| PolyPid Ltd. | -22.86 Million USD | 569.156% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 759.142% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 460.66% |
| Instil Bio, Inc. | -159.16 Million USD | 167.401% |
| argenx SE | -425.04 Million USD | 125.24% |
| Immunome, Inc. | -109.53 Million USD | 197.948% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 313.017% |
| Verona Pharma plc | -67.83 Million USD | 258.161% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 511.673% |
| Shattuck Labs, Inc. | -91.95 Million USD | 216.665% |
| CervoMed Inc. | -7.81 Million USD | 1473.14% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 246.741% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 905.36% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 322.697% |
| Moolec Science SA | -6.65 Million USD | 1712.341% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 752.232% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 179.335% |
| Design Therapeutics, Inc. | -78.19 Million USD | 237.207% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 223.255% |
| NeurAxis, Inc. | -6.66 Million USD | 1709.754% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 364.9% |
| Lumos Pharma, Inc. | -36.61 Million USD | 393.008% |
| Achilles Therapeutics plc | -75.25 Million USD | 242.558% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 511.673% |
| 180 Life Sciences Corp. | -13.47 Million USD | 896.008% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -1980.596% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 3757.775% |
| Nutriband Inc. | -4.87 Million USD | 2302.045% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 196.842% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 293.479% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 311.035% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 262.305% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 298.219% |
| Palisade Bio, Inc. | -13.07 Million USD | 920.826% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 336.257% |
| Beam Therapeutics Inc. | -176.48 Million USD | 160.788% |
| Neurogene Inc. | -55.58 Million USD | 293.012% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 198.285% |
| AEON Biopharma, Inc. | -48.42 Million USD | 321.524% |
| Sesen Bio, Inc. | -25.9 Million USD | 514.072% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 228.437% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 952.331% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 123.294% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 248.1% |
| Athira Pharma, Inc. | -125.46 Million USD | 185.507% |
| Vaccinex, Inc. | -22.88 Million USD | 568.787% |
| HCW Biologics Inc. | -25.71 Million USD | 517.161% |
| XOMA Corporation | -41.84 Million USD | 356.361% |
| Nektar Therapeutics | -137.42 Million USD | 178.066% |
| Arvinas, Inc. | -401.5 Million USD | 126.72% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 1213281.455% |
| Merus N.V. | -156.54 Million USD | 168.53% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 207.003% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 409.884% |
| Rezolute, Inc. | -70.42 Million USD | 252.339% |
| Clene Inc. | -40.54 Million USD | 364.632% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 755.018% |
| BeyondSpring Inc. | -23.11 Million USD | 564.143% |
| Synlogic, Inc. | -55.16 Million USD | 294.489% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 698.371% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 1091.149% |
| Peak Bio, Inc. | -1356.23 USD | 7910410.198% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 364.874% |
| Krystal Biotech, Inc. | -109.72 Million USD | 197.772% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 182.818% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 131.276% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 2360.494% |
| MannKind Corporation | 8.67 Million USD | -1136.253% |
| Ikena Oncology, Inc. | -75.41 Million USD | 242.252% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 1212.076% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 259.575% |
| Gossamer Bio, Inc. | -183.75 Million USD | 158.382% |
| CohBar, Inc. | -12.38 Million USD | 965.995% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 311.501% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 488.886% |
| Legend Biotech Corporation | -439.48 Million USD | 124.411% |
| Mural Oncology plc | -194.63 Million USD | 155.119% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 259.781% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 764.479% |
| Disc Medicine, Inc. | -91.12 Million USD | 217.731% |
| Champions Oncology, Inc. | -7.35 Million USD | 1558.428% |
| REGENXBIO Inc. | -268.12 Million USD | 140.011% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 1100.934% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 292.413% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 375.36% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 193.813% |
| Vaxart, Inc. | -83.34 Million USD | 228.717% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 1359.177% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 350.694% |
| Cellectis S.A. | -106.62 Million USD | 200.615% |
| Longeveron Inc. | -21.02 Million USD | 610.162% |
| Repare Therapeutics Inc. | -116.22 Million USD | 192.306% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 140.057% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 241.823% |
| Revolution Medicines, Inc. | -487.18 Million USD | 122.021% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 1712.778% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 344.078% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 243.829% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 254.063% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 1074.317% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 97.509% |
| Denali Therapeutics Inc. | -196.69 Million USD | 154.541% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 1339.3% |
| Veru Inc. | -93.78 Million USD | 214.395% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 559.865% |
| Cingulate Inc. | -22.75 Million USD | 571.379% |
| Passage Bio, Inc. | -108.38 Million USD | 198.979% |
| Context Therapeutics Inc. | -25.07 Million USD | 527.885% |
| Exicure, Inc. | -14.99 Million USD | 815.404% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 152.062% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 364.254% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 1204.072% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 158.193% |
| Nuvalent, Inc. | -149.49 Million USD | 171.764% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 1405.688% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 220.907% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 616.424% |
| OmniAb, Inc. | -69.41 Million USD | 254.543% |
| Anew Medical, Inc. | -1.3 Million USD | 8347.133% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 940.044% |
| Lipocine Inc. | -17.93 Million USD | 698.306% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 256.586% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 240.879% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 381.763% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 371.414% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 579.28% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 118.502% |
| Ocugen, Inc. | -65.53 Million USD | 263.712% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 214.293% |
| Q32 Bio Inc. | -92.1 Million USD | 216.482% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 600.406% |
| Alumis Inc. Common Stock | -158.17 Million USD | 167.825% |
| Equillium, Inc. | -14.52 Million USD | 838.755% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 271.91% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 1457.425% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 668.679% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 328.498% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 198.908% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 996.256% |
| Dominari Holdings Inc. | -21.79 Million USD | 592.21% |
| Edesa Biotech, Inc. | -9.22 Million USD | 1263.231% |
| vTv Therapeutics Inc. | -25.5 Million USD | 520.681% |
| Bio-Techne Corporation | 206.68 Million USD | 48.094% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 127.404% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 44.133% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 181.104% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 379.446% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 171.0% |
| Nkarta, Inc. | -131.65 Million USD | 181.49% |
| BioCardia, Inc. | -11.64 Million USD | 1021.35% |
| Iterum Therapeutics plc | -47.46 Million USD | 326.009% |